Noninvasive neuroimaging involves the use of a variety of imaging modalities to visualize the anatomy and activity of the brain without any invasive measures, such as taking tissue samples or performing surgery. It is a powerful tool for diagnosing and monitoring neurological conditions. Structural imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT), are used to identify changes in brain anatomy or assess the effects of age and head trauma. Functional methods, including functional MRI (fMRI) and positron emission tomography (PET) scans, allow us to map brain connectivity and monitor activity of the neurons. MRI is a non-invasive imaging method that uses magnetic fields and radio waves to visualise the internal anatomy and structure of the brain. It can detect abnormal fluid accumulation, lesions, tumors, and alterations in anatomy which may be caused by a disruption in the normal functioning of the nervous system. fMRI is a variation of MRI that can detect brain activity by measuring changes in oxygen levels in the blood. It is used to map the pathways of neural connectivity and assess the impact of neurological injury or disease on brain activity. PET is a more advanced form of functional imaging that involves the injection of a radioactive tracer into the bloodstream. The tracer travels to the brain and binds to target molecules associated with brain activity and metabolism, allowing researchers to track neural activity in real time. In addition to providing information on the brain activity, PET can be used to monitor the effects of drugs on the natural neurotransmitter systems of the brain.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States